NEW YORK, Nov. 23, 2016 /PRNewswire/ --
Plasma derived proteins are biological medicines used extensively in the treatment of rare, life-threatening, chronic, and genetic diseases. This report on the global plasma protein therapeutics market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, which includes a market snapshot providing overall information on various segments and sub-segments. This section also provides complete information and data analysis of the global plasma protein therapeutics market with respect to the leading market segments based on product type, application, and geography. The report is a robust combination of primary and secondary research. Primary research formed the bulk of our research efforts with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various national and international databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro-environmental factors. Growth rates for each segment within the global plasma protein therapeutics market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
Factors such as wide applications of human immunoglobulins and albumin, wide therapeutic areas, growing investment in research and development of new plasma proteins therapies, rising demand and widespread off-label use of IG are some of the major factors contributing to the rising demand for plasma proteins. Stringent regulations, reimbursement issues, and complexity of biologic manufacturing requirements are the major factors likely to hamper the plasma protein therapeutics market growth.
The market overview section of the report includes qualitative analysis of the overall plasma protein therapeutics market including the determining factors and the market dynamics such as drivers, restraints, and opportunities, along with Porter's Five Forces Analysis. In addition, market attractiveness analysis by geography and competitive landscape by key players have been provided which explains the intensity of competition in the market considering different geographies. The competitive scenario between market players has been evaluated through market share analysis. These factors would help the market players take strategic decisions in order to strengthen their positions and increase their shares in the global market.
The global plasma protein therapeutics market has been segmented based on product type, application, and geography. Based on product type, the global plasma protein therapeutics market has been categorized into immunoglobulins, albumin, coagulation factor, C1 esterase inhibitors and others. Hemophilia, primary immunodeficiency disorder, idiopathic thrombocytopenic purpura, secondary immunodeficiency, hereditary angioedema, and other indications form the major applications of the plasma protein therapeutics market. Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2014 to 2024 has been provided for all the segments, considering 2015 as the base year.
Geographically, the plasma protein therapeutics market has been categorized into five regions: North America, Europe, Asia Pacific, Latin America, and Rest of the World (RoW). The mentioned regions are further analyzed by major countries contributing largely to the market. The recommendations section included in the report are likely to assist the existing players to increase their market shares and new companies to establish their presence in the plasma protein therapeutics market. The report also profiles major players based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Major players in the global plasma protein therapeutics market are Baxter International, Biotest, CSL Behring, GRIFOLS, S.A., Kedrion, Octapharma USA, Inc., Shire Plc. and China Biologics. CSL Behring is the market leader in the plasma protein therapeutics market, while GRIFOLS, S.A leads the global market for IVIG and Alpha 1 antitripsin.
The global plasma protein therapeutics market has been segmented as follows:
Global Plasma Protein Therapeutics Market, by Product Type:
C1 esterase Inhibitors
Others (Alpha-1 proteinase inhibitors, hyper immune globulins)
Global Plasma Protein Therapeutics Market, By Application
Primary Immunodeficiency Disorder
Idiopathic Thrombocytopenic Purpura
Secondary Immunodeficiency (CLL, multiple myeloma, congenital aids, etc.)
Others (Kawasaki Disease, GBS, CIDP, etc.)
Global Plasma Protein Therapeutics Market, by Geography
Rest of Europe
Rest of APAC
Rest of the World (RoW)
Read the full report: http://www.reportlinker.com/p04086942-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001